Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Nom du journal : The Lancet Oncology
Année : 2020
Volume : 21
Page de départ : 1353
Page de fin : 1365